Analyst Ratings for Intellia Therapeutics
Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
EF Hutton Maintains Buy on Intellia Therapeutics, Lowers Price Target to $116
EF Hutton analyst Michael King maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the price target from $123 to $116.
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell
• ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
Cantor Fitzgerald initiated coverage on Editas Medicine Inc (NASDAQ:EDIT) with an Overweight rating and a price target of $15. The analyst says…
Cantor Fitzgerald Initiates Coverage On Intellia Therapeutics with Overweight Rating, Announces Price Target of $67
Cantor Fitzgerald analyst Rick Bienkowski initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Overweight rating and announces Price Target of $67.
JMP Securities Downgrades Intellia Therapeutics to Market Perform
JMP Securities analyst Silvan Tuerkcan downgrades Intellia Therapeutics (NASDAQ:NTLA) from Market Outperform to Market Perform.
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 325 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
Thursday's session saw 329 companies set new 52-week lows.
Intellia Therapeutics Announces Pricing Of ~$300M Public Offering Of 6,550,219 Shares Of Common Stock At A Price Of $45.80/Share
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced today the pricing of an
Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%
Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics shares fell 3% to close at $53.30 on Monday.